Drug Profile
Mercaptamine ophthalmic - Orphan Europe
Alternative Names: CYSTADROPS; Cystadrops; Cysteamine chlorhydrate - Orphan Europe; Cysteamine hydrochloride - Orphan Europe; Mercaptamine hydrochloride - Orphan EuropeLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Orphan Europe
- Developer Orphan Europe; Recordati Rare Diseases
- Class Anti-inflammatories; Antibacterials; Antidotes; Hepatoprotectants; Mercaptoethylamines; Mucolytics; Small molecules
- Mechanism of Action Glutathione synthase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cystinosis
Most Recent Events
- 28 Sep 2022 Phase III development is still ongoing for Cystinosis (In infants) in United Kingdom, France, Germany, Italy, Belgium (Ophthalmic) (EudraCT-2018-002984-24)
- 15 Sep 2020 Launched for Cystinosis (In adolescents, In children, In adults) in USA (Ophthalmic)
- 25 Aug 2020 Efficacy and safety data from phase I/IIa trial in Cystinosis released by Recordati Rare Diseases